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Abstract 
For the production of tumor-specific vaccines, including dendritic cell (DC) vaccines, the tumor cells themselves are 
an ideal source. Floating tumor cells in the ascites fluid from patients with malignant ascites are a good candidate 
source, but it is not easy to obtain pure tumor cells from ascites because of various types of cell contamination as well 
as protein aggregates. We here report an effective method to recover pure tumor cells from malignant ascites. We 
used lavage fluid from 13 patients with malignant ascites who were treated with modified cell-free and concentrated 
ascites reinfusion therapy (KM-CART). Cellular components were separated from the lavage fluid by centrifugation, 
enzymatic digestion and hemolysis. Tumor cells were purified by depleting CD45+ leukocytes with antibody-conju-
gated magnetic beads. The tumor cell lysate was extracted by freeze-and-thaw cycles. The mean obtained total cell 
number was 7.50 × 107 cells (range 4.40 × 106–2.48 × 108 cells). From this fraction, 6.39 × 106 (range 3.23 × 105–
2.53 × 107) CD45− cells were collected, and the tumor cell purity was over 80 % defined as CD45−CD326+. A suf-
ficient amount of tumor lysate, average  = 2416 μg (range 25–8743 μg), was extracted from CD45−CD326+ tumor 
cells. We here established an effective method to produce highly purified tumor cells from KM-CART lavage fluid. The 
clinical feasibility of this simple preparation method for generating tumor lysate should be examined in clinical stud-
ies of DC vaccines.
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Background
Cancer vaccines targeting tumor-specific antigens, 
including dendritic cell (DC) vaccines, are a promis-
ing alternative against malignancies. Dendritic cells are 
unique antigen-presenting cells (APCs) that can stimu-
late innate and acquired immune responses. We have 
conducted several clinical trials in which we observed no 
serious adverse events related to DC vaccination (Taka-
hashi et al. 2013; Kobayashi et al. 2013, 2014a, b). We also 
found that the combination therapy of DC vaccines and 
an activated T cell infusion could be an effective treat-
ment for patients with pancreatic cancer (Kimura et  al. 
2012). For antigen-loaded DCs, synthetic peptides can be 
prepared uniformly and according to the expression pat-
terns on tumor tissue, but it has been difficult to adapt 
such peptides to tumor antigenic mutation. Moreover, 
synthetic peptides are restricted by the HLA of patients.
Alternatively, the autologous tumor lysate could have 
the following advantages: (a) it could provide multiple 
antigenic epitopes for recognition by specific T cells. 
Tumors are heterogeneous cell populations among indi-
viduals, and they contain unidentified tumor-associated 
antigens (TAAs). (b) Targeting multiple antigens could 
be advantageous and may eliminate the need for the 
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immune selection of single-antigen-loss tumor variants 
(Fields et al. 1998; Shimizu et al. 1999). Thus, tumor cells 
in the ascites from patients are a good candidate source 
for tumor-specific vaccines.
Malignant ascites (MA) is defined by the US National 
Cancer Institute (NCI) as “a condition in which fluid con-
taining tumor cells collects in the abdomen” and it repre-
sents an advanced state of ovarian, pancreaticobiliary, or 
gastrointestinal cancer (Chung and Kozuch 2008). Malig-
nant ascites causes severe abdominal distension, dyspnea 
and loss of appetite, and it can thus result in reduced activi-
ties of daily living and quality of life. Cell-free and concen-
trated ascites reinfusion therapy (CART) is a therapeutic 
method in which the ascitic fluid or pleural fluid is collected 
from a patient with ascites, and then cellular components 
including bacteria and leukocytes are removed by filtration. 
The conventional CART system uses a complicated circuit 
and requires handling via a special pump system. Further-
more, it has an unsatisfactory filtration capacity with the 
membrane becoming clogged after filtration of about 2  L 
of cancerous ascites. On the other hand, the previously 
developed KM-CART system has a simpler circuit and 
employs an external pressure system with a membrane-
cleaning function that can collect filtrated cells from lavage 
fluid (Matsusaki et al. 2011a). Thus, in the present study, we 
attempted to recover purified tumor cells from KM-CART 
lavage fluid and to obtain the cell lysate for DC vaccines.
Methods
Patients
The collection and analyses of KM-CART lavage fluid 
from 13 cancer patients were done with written informed 
consent under the approval of the Institutional Review 
Board of Kyushu University. The characteristics of the 
patients are summarized in Table 1.
Cell preparation
KM-CART was conducted as described (Matsusaki et  al. 
2011b). KM-CART lavage fluid was kept at 4 °C until use (for 
2–3 days). The cellular fraction was separated by centrifuga-
tion at 1500g for 5 min and washed once with RPMI-1640. 
Minced large clusters were digested by collagenase (50 μg/
mL, Nacalai Tesque, Kyoto, Japan) and DNase I (100 μg/mL, 
Roche Diagnostics, Basel, Switzerland). The erythrocytes 
were then burst in pure water for 60 s, and the remaining 
cells were washed with polymyxin B solution (50,000 U/mL, 
Sigma-Aldrich, St. Louis, MO) and passed through 100 μm 
nylon cell strainer (CORNING, New York, NY). For tumor 
cell enrichment, CD45+ cells were depleted with CD45-
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturer’s instructions.
Flow cytometric analysis
The cells from KM-CART lavage fluid were stained with 
the following FITC-, PE-, or PerCP-Cy5.5-conjugated 
monoclonal antibodies (mAbs): CD3, CD4, CD8, CD11b, 
CD19, CD25, CD33, CD45, and CD326 (BioLegend, San 
Diego, CA). The appropriate conjugated isotype-matched 
IgGs were used as controls. The cells were analyzed using 
a FACSCalibur and CellQuest software (Becton–Dickin-
son, Lincoln Park, NY). The final data were prepared with 
FlowJo 7.6 software (Tree Star, Ashland, OR).
Wright–Giemsa staining
The cells from KM-CART lavage fluid were morphologi-
cally assessed using the Wright–Giemsa staining method. 
Cells were prepared on slides by a Cytospin (Shandon 
Southern, UK) and stained with Wright–Giemsa stain. 
The cell morphology was examined under a light micro-
scope, BZ-9000 (KEYENCE, Osaka, Japan).
Tumor cell lysate preparation
CD45-depleted cells were re-suspended in D-PBS(−) 
(Wako, Japan) and lysed by five freeze (in liquid N2)/thaw 
(in 37  °C water bath) cycles followed by centrifugation. 
Lysate was centrifuged at 15,000g for 30 min at 4 °C. The 
supernatant was recovered and the protein content was 
measured with a NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA).
Statistical analyses
All data are expressed as the mean ± SEM. The data were 
examined using the Mann–Whitney U-test.
Results
Schematic diagrams of the tumor cell-recovery system 
are shown in Fig. 1. Filtrated cells from the lavage fluid of 
CART for cancerous ascites were collected from 13 sub-
jects with various types of malignancies (Table 1).











Median amount of removed ascites (mL) 5900a
(2800–11,500)
Median amount of lavage fluid (mL) 1700a
(800–6800)
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Typical clusters of tumor cells and white blood cells 
(WBCs) were observed in the lavage fluid, and tumor 
cells were highly enriched after separation/enrichment 
(Fig.  2a). After the separation steps (centrifugation, 
enzymatic digestion, red blood cell (RBC)-burst, poly-
myxin B treatment and filtration), the mean obtained 
total cell number was 7.50 × 107 cells (range 4.40 × 106–
2.48  ×  108 cells). After the enrichment step (after 
CD45-depletion), the mean obtained total cell number 
was 6.39 × 106 cells (range 3.23 × 105–2.53 × 107 cells) 
(Fig. 2b).
We analyzed the constitution of the collected cells 
using CD45 (WBCs) and CD326 (tumor cells) as cell 
markers. CD326 (epithelial cell adhesion molecule; 
EpCAM) was originally the epithelial cell marker, and it 
has been reported to be expressed by approx. 87–100 % 
Fig. 1 Schematic diagrams of the KM-CART tumor cell-recovery system. Cellular components (blood cells, tumor cells, etc.) are collected by the 
KM-CART system, and then the separation and enrichment of tumor cells (CD45−/EpCAM+) is performed. a Processing of ascites. b Processing of 
lavage fluid
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of the main ascites-causing carcinomas (Passebosc-Faure 
et al. 2005; De Angelis et al. 1992; Diaz-Arias et al. 1993; 
Went et al. 2004). In the present study, the separated cells 
contained a large number of CD45+ (leukocyte-specific 
antigen) cells (32.96–99.44  %) (Fig.  3a, left panel), and 
we thus attempted to enrich the tumor cells by CD45 
depletion. Through this enrichment step, CD45+ cells 
were removed and CD45−/EpCAM+ tumor cells were 
enriched (Fig.  3a, right panel). Although measurable 
debris has been detected (fluorescence intensity <2×100), 
the following step (lysate extraction) was carried out 
without difficulties.
The mean CD45+ and CD45−/EpCAM+ contents are 
shown in Fig. 3b,c. After the enrichment step, the mean 
yield CD45−/EpCAM+ cell number [mean yield total cell 
number × CD45−/EpCAM+ (%)] was 6.34  ×  106 cells 
(range 4.74 × 104–2.53 × 107 cells) (Fig. 3d). In contrast, 
the mean yield CD45 + cell number [mean yield total 
cell number × CD45 + (%)] was 5.40 ×104 cells (range 
3.30 ×  103–4.19 ×105 cells) (Fig.  3e). Summary of KM-
CART and total cells and tumor cells acquired after 
enrichment step is shown in Table 2.
The recovery efficiency of CD45+ cells was 0.30  % 
(0.01–2.67  %), and that of CD45−/EpCAM+ cells was 
Fig. 2 Collection of cell components from lavage fluid. Total cellular components were separated from KM-CART lavage fluid by centrifugation, 
enzymatic digestion, RBC-burst, polymyxin B treatment and filtration (separation steps) followed by CD45− depletion (enrichment step). a Wright–
Giemsa-stained cytocentrifuge preparations are shown. Bars 40 μm. b The mean obtained total cell numbers. After the separation steps: 7.50 × 107 
cells, and after the enrichment step: 6.39 × 106 cells
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49.07  % (7.00–94.90  %) (Fig.  4a). Finally, the tumor 
lysate was extracted from purified CD45−/EpCAM+ 
tumor cells. The mean yield amount of tumor lysate was 
2416.87 μg (range 25–8743 μg) (Fig. 4b).
Discussion
Latifi A et al. reported that the tumor cells in the ascites 
of the patients had an antigenic phenotype that was iden-
tical to that of their solid tumor counterpart (Latifi et al. 
2012). Provencher et  al. also reported that tumor cells 
from malignant tissue and ascetic fluid resembled the 
antigenic phenotype (Provencher et  al. 1993). Thus, the 
tumor cell lysate from ascites could be an ideal source 
with which to produce tumor-specific vaccines.
The results of the present study showed that highly 
purified tumor cells and tumor cell-associated protein 
could be obtained from KM-CART lavage fluid in a 
simple manner. Filtration (Hirte et  al. 1992), peptide-
conjugated nanoparticles (Scarberry et  al. 2010), den-
sity gradient centrifugation (Hamburger et al. 1985) and 
magnetic beads (Barker et al. 2001; Chan et al. 2007) have 
been used to separate tumor cells from malignant ascites. 
Among these methods, magnetic cell separation might be 
useful for the enrichment of tumor cells because of the 
high purity and high yield it can provide. However, due 
to the solidification of the content during the shipping of 
Fig. 3 Enrichment of tumor cells for tumor lysate. a A typical 
dotplot pattern of post-separation and post-enrichment cells. Cells 
were stained with monoclonal antibodies and were defined as 
CD45+CD326−; the tumor cells were CD45−CD326+. b The frequen-
cies of CD45+ cells (WBC). c The frequencies of CD45−/EpCAM+ cells 
(tumor cells). d The cell number of CD45+ cells (WBC). e The cell 
number of CD45−/EpCAM+ cells (tumor cells)
Table 2 Summary of  KM-CART and  total cells and  tumor 
cells acquired after enrichment step











1 3750 800 18.6 18.5
2 5900 3000 17.8 17.8
3 4900 1700 0.07 0.06
4 6400 3150 25.3 25.3
5 5100 2560 2.10 2.09
6 8050 6800 6.72 6.70
7 4500 1700 0.78 0.77
8 2800 1700 0.32 0.28
9 7000 2630 0.47 0.47
10 3800 1580 1.60 1.59
11 11,500 1000 8.64 8.56
12 9300 6400 0.13 0.12
13 8500 1600 0.64 0.61
Fig. 4 Protein contents extraction from tumor cells. Protein contents 
were extracted from enriched tumor cells by the freeze and thaw 
method. a Recovery efficiency of WBC (CD45+) and tumor cells 
(CD45−/EpCAM+). b Protein yield from total ascites
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the ascites, the magnetic separation column can become 
clogged. Cold-induced precipitation of cryogel from 
plasma has been reported by Morrison et  al. (Morrison 
et al. 1948). Cryogel is a physical gel formed by the heter-
ophilic aggregation of fibronectin, fibrinogen and heparin 
(Miyamoto et  al. 2001). In our KM-CART method, the 
solid contents containing tumor cells in the ascites were 
treated with collagenase, and thus the mAb-conjugated 
magnetic beads’ access to target cells might be improved, 
efficiently separating the cells. The clinical feasibility of 
our simple preparation method for generating tumor 
lysate should therefore be examined in clinical studies of 
DC vaccines.
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